Emicenter Napoli reports successful clinical usage of AI software Quantib™ Neurodegenerative

Rotterdam, The Netherlands | Naples, Italy | February 2019

Emicenter Naples, a multi-specialized healthcare facility in Naples, successfully applies AI software Quantib™ ND in their clinical routine. Quantib’s state-of-the-art neurology software includes a wide range of functionalities for quantification and tracking of brain atrophy and white matter hyperintensities (WMHs). Quantib™ ND provides objective information on changes in the brain related to e.g. dementia and multiple sclerosis (MS).

Rossana Senese, MD, states: “We are very proud and excited that together with Quantib we have installed the Quantib AI software and integrated it seamlessly into our radiology workflow. We use the software for all our dementia cases. By leveraging  the quantitative information and the opportunity to compare patient results to the average of a cross section of the population the software enables our radiologists to deliver clear, detailed and structured information on the brain condition of the patient.”

“With our new software release in July 2018 the possibilities of Quantib™ ND have extended considerably,” says Arthur Post Uiterweer, CEO of Quantib. “We are very proud that a leading institute such as Emicenter puts their faith in our software to provide quantitative information physicians can leverage during diagnoses processes.”

Quantib presents major upgrade of dementia and MS diagnosis support software

In July of 2018 Quantib released a major upgrade of their brain atrophy and WMH tracking software Quantib™ ND. A substantial list of new tools was added to previous software functionalities resulting in a unique radiology software product.

Rudolf Scholte, COO of the company, emphasizes the significance of the release. He stated, “You should actually think of this product as two combined in one. The software includes an exhaustive atrophy measurement tool and a WMH tracking tool. These two neurological biomarkers are relevant for both MS and dementia; therefore, we decided to bundle the tools into one product.”

Quantib™ ND is CE marked and available throughout Europe for specialists to use in their diagnosis process. Additionally, the software received FDA clearance end of 2018. The software may be integrated into the current (PACS) workflow of radiology departments, making the results accessible directly from the PACS worklist. Alternatively, it may be installed as a dedicated post-processing workstation for the heavy users.

About Neurodegenerative Disorders

In the upcoming decennia, neurodegenerative diseases will have an enormous impact on society. The Alzheimer’s Association estimated in their 2015 World Alzheimer Report that the world will count ~100M people with Alzheimer’s in 2014.1 Last year, Bill Gates announced that he will invest $30M in the improvement of diagnosis of Alzheimer’s disease to support cutting back the rates of neurodegenerative diseases.2

Although some risks are genetically determined, a recent publication in the Lancet shows that 35% of risk factors are modifiable. Therefore, early discovery of dementia or of mild cognitive impairment (often a pre-stage of dementia) is of great importance. Additionally, this paper demonstrates clearly how clinical research in the field of dementia is progressing rapidly. Quantib™ ND is eminently suitable in the acceleration of this research even further and improves accuracy by quantifying results.3

About Quantib

Quantib, market leader in artificial intelligence tools for radiology, strives for faster and more accurate diagnoses, supporting adequate and timely patient care. Using advanced machine learning techniques, Quantib’s products can detect changes in tissue sooner than would be possible with the naked eye. Quantib has multiple machine-learning products cleared by FDA and/or CE marked. These products are focused detection of changes in the brain related to diseases such as dementia and MS. Simultaneously, the company is collaborating with, amongst others, Erasmus MC Rotterdam and UMC Utrecht, for the development of other AI applications.

For more information on Quantib and their products please visit www.quantib.com/solutions

 Bibliography

  1. Prince, Martin; Wimo, Anders; Guerchet, Maëlenn; Ali, Gema-Claire; Wu, Yu-Tzu; Prina, M. World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer’s Dis. Int. 1–88 (2015). doi:10.1111/j.0963-7214.2004.00293.x
  2. Gates, B. Gatesnotes. Why diagnosing Alzheimer’s today is so difficult—and how we can do better (2018). Available at: https://www.gatesnotes.com/Health/A-better-way-of-diagnosing-Alzheimers?WT.mc_id=20180717193325_AlzheimersBiomarkers_BG-LI&WT.tsrc=BGLI&linkId=54393851.
  3. Livingston, G. et al. Dementia prevention, intervention, and care. Lancet 390, 2673–2734 (2017).